The effects of the proton pump inhibitor lansoprazole on the bioavailability of a lowdose oral contraceptive (OC), containing 0.03 mg ethinyloestradiol (EE) and 0.15 mg levonorgestrel (LNG), were investigated. Twenty-four healthy females (aged 19-35 years; weight 60.6 ± 7.1 kg) participated in a multiple-dose, placebo-controlled, randomized two-way cross-over study. All subjects received the OC over 2 full menstrual cycles from day 1 to day 21 separated by a drug-free interval of 7 days. Lansoprazole (60 mg day-') or placebo was coadministered for 3 weeks each. Plasma concentrations of EE and LNG were determined by GC-MS. The 90% confidence intervals for ratios of Cmax and AUC after log transformation of both EE and LNG ranged between 91 and 111%, indicating that lansoprazole did not affect the bioavailability of EE and LNG.
Introduction
Since proton pump inhibitors are often used concomitantly with other drugs, their potential for drug interactions should be assessed [1, 2] . Omeprazole, for instance, dose-dependently inhibits the hepatic elimination of diazepam [3, 4] , carbamazepine [5] , possibly of phenytoin [3, [6] [7] [8] , and to a small extent that of aminopyrine [9] and (R)-warfarin [10] . It also induces the expression and activity of cytochromes P450 lAl/2 [11] [12] [13] [14] , inhibits adrenocortical steroidogenesis [15] but fails to alter 2-hydroxylation of oestradiol in males [16] .
In contrast, lansoprazole does not affect the pharmacokinetics of warfarin [17] and diazepam [18] . While antipyrine clearance is slightly reduced with omeprazole [9] and slightly increased with lansoprazole [19] , theophylline clearance is marginally increased with both drugs [20, 21] .
Younger female patients often use oral contraceptives (OC) and their efficacy might be affected by other drugs. Therefore, the present study was performed to assess any effects of lansoprazole in female subjects taking OC. The multiple-dose, placebo-controlled cross-over study lasted for two menstrual cycles. During both cycles subjects took their OC (Microgynon 21® (0.03 mg ethinyloestradiol (EE) + 0.15 mg levonorgestrel (LNG)), Schering AG, Berlin) as usual from day 1 to day 21, followed by a wash-out period of 7 days. Blinded and randomized coadministration comprised either a single daily oral dose of 60 mg lansoprazole (Agopton®, Takeda Pharma GmbH, Aachen) or placebo from day 1 to day 21 of the first cycle. During the second cycle (day 29 to 49) the subjects received the other concomitant medication. The dosage of lansoprazole was fixed at twice the recommended dosage in order to facilitate detection of a possible interaction.
Intake of medication was scheduled every day before breakfast with 180 ml water at the study site. No concomitant medication was allowed or given during the study. On study days 13, 20, 41, and 48 the subjects were confined to the research ward from 18.00 h onwards for 37 h for the pharmacokinetic measurements.
Prior to the start of the study and on study days 14 and 21 of each cycle blood samples (15 ml) were taken before administration and at 1, 1.5, 2, 4, 8 and 24 h after drug intake. Plasma was harvested (Liheparinised Becton-Dickinson Plasma Vacutainers®) and deep-frozen until analyzed. Twenty-four hour urine was collected on days 14 and 21 of each period.
The endocrine parameters FSH, LH, progesterone, 17-.-oestradiol and SHBG were monitored on study days 7, 14 and 21 in each period using one 5 ml blood sample drawn into serum Monovettes® (Sarstedt).
ml) and acetonitrile (to 1000 ml), and u. A 12 h urine sample collected during screening was used to phenotype the subjects for sparteine [23] ml-' to 500 pg ml-' and 0.2 ng ml-' to 20 ng ml-', respectively. The inaccuracy was below 3% (EE) and 6% (LNG) and the imprecision (coefficient of variation) was below 10% (EE) and 7.5% (LNG) at all concentrations.
Unchanged lansoprazole was analysed after solidliquid extraction by h.p.l.c. using a slight modification of a published method [22] . The [27, 28] .
Results
Measurement of plasma lansoprazole concentrations confirmed that the subjects were compliant with drug dosage and that therapeutically effective levels of lansoprazole had been achieved (see Table 2 ).
Urinary excretion of D-glucaric acid and 6-fhydroxycortisol were comparable with published data [25, 29] . As shown in Table 1 the excretion of both marker compounds was unaffected by lansoprazole (P > 0.05, Wilcoxon test).
Plasma concentrations of EE and LNG were similar during all four monitored dosing intervals and were consistent with published data [30] [31] [32] [33] [34] [35] [36] [37] . No individual displayed a consistent decrease in plasma concentration of either EE or LNG on the two study days. The 90% confidence intervals (ranging from 91.3 to 110.6%) indicated bioequivalence between the two treatments for all three kinetic parameters (AUC(0,24) ,Cmax, tmax).
During intake of lansoprazole and placebo minor changes in hormone levels were observed over the 3 weeks of monitoring but they were independent of comedication (see Table 1 ).
Discussion
The results indicate that, in female subjects, a relatively high dose of 60 mg lansoprazole once daily does not alter plasma concentrations of EE and LNG provided by the regular intake of a widely used lowdose OC. Moreover, normal excretion of D-glucaric acid and 6-,B-hydroxycortisol, two established probes for assessing induction of hepatic drug metabolism [38, 39] , indicate that lansoprazole is not an inducer of the enzymes marked by these compounds. Neither exogenous nor endogenous hormone levels were altered by 3 weeks' adminstration of high-dose lansoprazole. Minor changes in hormone levels were independent of comedication and represented normal time (cycle)-dependent fluctuations in female subjects during regular intake of OC [40, 41] . No elevation of endogenous progesterone occurred to suggest ovulation during either phase of the study. Except for one individual (number 22) the treatment with lansoprazole was well-tolerated. This subject had normal plasma drug concentrations in all analyses and was an EM of sparteine and mephenytoin. The reported minor side-effects in the other subjects (e.g. headache, gastrointestinal disturbances, common cold symptoms) were randomly distributed with regard to time and drug treatment.
In conclusion, we have found no evidence for a pharmacokinetic interaction between lansoprazole and components of the low dose oral contraceptive pill.
